A study by Joseph et al. in this issue of the journal examined the safety and efficiency of redeploying a transcatheter aortic valve replacement (TAVR) service during the COVID-19 pandemic [1]. Given the strain on the healthcare system and restriction of services during this contemporary and unprecedented crisis, the authors undertook a pilot study to evaluate the feasibility of a TAVR service streamlined in less than a week to address urgent and emergent cases of severe and symptomatic aortic stenosis. An experienced team was, therefore, moved from a tertiary surgical center with a high COVID-19 admission burden to a hospital with no previous experience in percutaneous valve intervention nor an intensive care unit (ICU) or on-site cardiac surgery.